Navigation Links
Second Successful Quigley QR-443 Study Suggests Method of Action,Relevant to Broad Range of Chronic Inflammatory Diseases - Human,Study to Follow -

DOYLESTOWN, Pa., June 20, 2007 /PRNewswire-FirstCall/ -- Quigley Pharma,, a wholly owned subsidiary of The Quigley Corporation announced today that it has completed a follow-up study to evaluate the impact of QR-443 on levels of a pro-inflammatory cytokine Interleukin-6 (IL-6) in a cachexia model. This new data concluded that responding mice had lower levels of serum IL-6 when administered QR-443 orally than mice that received placebo. This reduction in IL-6 suggests a method of action for the delayed onset and reduced severity of cachexia observed in this study as well as the previously conducted cachexia model study.

QR-443 was formulated with the intention to impact metabolic imbalances and chronic inflammation. Cachexia is an extremely debilitating and life threatening, wasting syndrome associated with chronic diseases such as cancer, AIDS, chronic renal failure, COPD and rheumatoid arthritis, where inflammation has a significant impact and patients experience loss of weight, muscle atrophy, fatigue, weakness and decreased appetite.

A reduction in IL-6 is associated with a reduction in inflammation and suggests that QR-443 may have a role in a broad range of chronic inflammatory diseases. The Company has begun developing a human study protocol to evaluate the safety and impact of this compound on specific metabolic processes altered by chronic inflammation and the presence of IL-6.

Chronic inflammation is also associated with other disorders such as rheumatoid arthritis, metabolic syndrome, COPD, AIDS and cancer and can cause physical, metabolic and physiological limitations. Interleukin-6 (IL-6) is a pro-inflammatory cytokine secreted to stimulate an immune response to trauma and disease leading to inflammation. Inflammation and the presence of IL-6 have been shown to negatively effect "normal" metabolic processes and pathways - a disruption of homeostasis.

Dr. Richard Rosenbloom EVP/COO Quigley Pharma, Inc. stated, "We are encouraged by these and previous results and are looking forward to subjecting the compound to more rigorous tests to support eventual commercialization."

About The Study

The study results demonstrated a correlation to the levels of serum IL-6 and the degree of cachexia. Mice responding to QR-443 treatment had much lower levels of serum IL-6 which correlated with reduced cachexia, compared to non responders and the control population who had elevated IL-6 and dramatic weight loss. These findings are in agreement with several previous studies demonstrating the increased presence of IL-6 in the etiology of cachexia and other diseases related to inflammation.

The purpose of the study was to replicate positive oral dose response trials in BALB/C mice as well as to investigate the possible relationship of the levels of interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-alpha) and interferon gamma (IFN-gamma) cytokines which have been associated with the severity and progression of cachexia. In this experiment a larger group of mice was used, their weight being recorded and blood being drawn prior to the onset of cachexia and then at the peak of cachexia which marked the end of the experiment. There was no correlation between the levels of TNF-alpha and the severity of cachexia and levels of IFN-gamma were lower than the detectable assay level.

The Quigley Corporation makes no representation that the U.S. Food and Drug Administration or any other regulatory agency will allow the aforementioned Compound to be tested in humans or marketed. Furthermore, no claim is made that the potential medicine discussed here is safe, effective, or approved by the Food and Drug Administration.

About The Quigley Corporation

The Quigley Corporation is a diversified natural health medical science company. Its Cold Reme dy segment is a leading marketer and manufacturer of the COLD-EEZE(R) family of lozenges, gums and sugar free tablets clinically proven to cut the common cold nearly in half. COLD-EEZE customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation has four (4) wholly owned subsidiaries. Darius International markets health and wellness products through its wholly owned subsidiary, InnerLight Inc. Quigley Manufacturing Inc. consists of two FDA approved facilities to manufacture COLD- EEZE(R) lozenges as well as fulfill other contract manufacturing opportunities. Quigley Pharma Inc. ( conducts research in order to develop and commercialize a pipeline of patented botanical and naturally derived prescription drugs.

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.

    CONTACT:  Media                       Investor Relations

              Karen Pineman               Carl Hymans

              G.S. Schwartz & Co.         G.S. Schwartz & Co.

              212.725.4500                212.725.4500


CONTACT: Med ia, Karen Pineman, ; investors, or CarlHymans, , both of G.S. Schwartz & Co., +1-212-725-4500

Web site:

Ticker Symbol: (NASDAQ-NMS:QGLY)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
4. NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
5. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
6. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
7. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
8. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
9. Gilead Announces Achievement of Primary Efficacy Endpoint in Second Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
10. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
Post Your Comments:
(Date:11/24/2015)... and BERN, Switzerland , ... the ARTORG Center for Biomedical Engineering Research of the ... the Division of Endocrinology, Diabetes and Clinical Nutrition of ... the start of an exclusive collaboration to develop a ... algorithm for the personalised delivery of insulin for diabetic ...
(Date:11/24/2015)... st  Scientific Assembly and Annual Meeting of the Radiological Society ... Chicago on Nov-29 th through Dec-4 ...  Scientific Assembly and Annual Meeting of the Radiological Society of ... Chicago on Nov-29 th through Dec-4 th , ... present its revolutionary whole body CZT digital SPECT/CT solution at the ...
(Date:11/24/2015)... , November 24, 2015 The uptake of recently ... be a key driver of market growth to 2021, ... approved and pipeline premium products for Type 1 Diabetes Mellitus (T1DM), will ... says GBI Research . --> The uptake of ... will be a key driver of market growth to 2021, ...
Breaking Medicine Technology:
(Date:11/24/2015)... M.D. (PRWEB) , ... November 24, 2015 , ... ... new award for its exceptional customer service: the TrustDale certification. The award recognizes ... The Baltimore stone honing , tile and grout, and hard surface restoration ...
(Date:11/24/2015)... ... November 24, 2015 , ... Autism Speaks, the world’s leading ... driven by social media and the generosity of people around the world. On December ... media networks to give – and share the personal stories behind those gifts. ...
(Date:11/24/2015)... ... ... Peck’s mother wondered if she was a descendant of Samuel Fuller, a passenger on the ... for information, Don and his aunt discovered that she was not, in fact, related to ... Don’s father who was descended from not one, but four passengers on the famed ship ...
(Date:11/24/2015)... ... 2015 , ... Dehydration, defined as a loss of body water content, can ... sun, and heat stroke and death will quickly follow. A normal human body is ... cell, system and structure requires water to function properly. Kleyne, who believes that medical ...
(Date:11/24/2015)... CA (PRWEB) , ... November 24, 2015 , ... ... College District , the only authorized OSHA Training Institute Education Center in Northern ... injuries during the holiday season’s major sales events. As the volume of ...
Breaking Medicine News(10 mins):